Clinical Trials

CNS

Glioblastoma

NCT06210334 2024-02-20

HAI-TL

54 enrolled

Carcinoma, Hepatocellular

NCT06235918 2024-02-01

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck

NCT04914390 2024-01-22

NeoATCT

32 enrolled

Breast

Triple Negative Breast Neoplasms

NCT05435313 2024-01-17

Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy

39 enrolled

Colorectal Neoplasms

NCT06197438 2024-01-09

Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer

36 enrolled

Stomach Neoplasms

NCT05611879 2023-12-29

Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC

Carcinoma, Non-Small-Cell Lung

NCT05578287 2023-12-07

DETECT

29 enrolled

Colorectal Neoplasms

NCT05588219 2023-11-24

Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

Gynecologic

Uterine Cervical Neoplasms

NCT04734262 2023-11-18

SPARK

98 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06134193 2023-11-18

Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer

41 enrolled

Carcinoma, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06059885 2023-09-29

Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC

60 enrolled

Liver Neoplasms

NCT05228496 2023-09-26

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC

21 enrolled

Small Cell Lung Carcinoma

NCT04902261 2023-09-01

Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer

140 enrolled

Pancreatic Neoplasms

NCT05823987 2023-06-27

OPTIONS-05

Advanced Biliary Tract Cancer

NCT05893056 2023-06-27

CASTLE-09

Gastric Cancer Metastatic to Liver

NCT05897268 2023-06-27

CASTLE-10

Carcinoma, Hepatocellular

NCT05751265 2023-06-22

Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer

39 enrolled

Stomach Neoplasms

NCT05900921 2023-06-13

Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

132 enrolled

Advanced Squamous Non-Small-Cell Lung Cancer

NCT05681390 2023-06-09

Tislelizumab With Anlotinib and Chemotherapy for Second-line Treatment of Pancreatic Cancer

Pancreatic Neoplasms

NCT05896059 2023-06-09

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC

21 enrolled

Extensive Stage Small Cell Lung Cancer

NCT05420584 2023-05-11

NECI

83 enrolled

Rectal Neoplasms

NCT04542369 2023-05-03

Pilot Study of PD-1inhibitor (Tislelizumab) Plus Chemotherapy as Neoadjuvant Therapy for Limited-Stage Small-Cell Lung Cancer

15 enrolled

Small Cell Lung Carcinoma

NCT05400902 2023-04-13

HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma

17 enrolled

Cholangiocarcinoma

NCT05799443 2023-04-05

Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer

23 enrolled

Colorectal Neoplasms

NCT04663035 2023-03-22

Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage HCC

120 enrolled

Carcinoma, Hepatocellular

NCT05775874 2023-03-20

A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC

80 enrolled

Carcinoma, Transitional Cell

NCT04985721 2023-03-15

IMPARP-HRD

60 enrolled

Tumor-Agnostic

Neoplasms

NCT05445648 2022-12-28

CBPTMI

65 enrolled

Urinary Bladder Neoplasms

NCT05659186 2022-12-21

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

20 enrolled

Thyroid Neoplasms

NCT05634564 2022-12-05

Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer

62 enrolled

Pancreatic Neoplasms

NCT04730219 2022-11-30

Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma

48 enrolled

Carcinoma, Transitional Cell

NCT05596890 2022-11-28

PICCRT

50 enrolled

Esophageal Squamous Cell Carcinoma, Deglutition Disorders

NCT05406466 2022-11-10

Cryoablation Combined With Tislelizumab Plus Lenvatinib in Patients With Melanoma Liver Metastasis

Dermatologic

Melanoma

NCT05493683 2022-10-21

Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer

29 enrolled

Colorectal Neoplasms

NCT05545124 2022-09-19

Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence

32 enrolled

Carcinoma, Hepatocellular

NCT05036798 2022-09-07

Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.

Potentially Resectable Locally Advanced Malignant Tumors of Biliary System

NCT05314101 2022-08-23

TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer

Colorectal Neoplasms

NCT05401279 2022-08-18

Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer

20 enrolled

Urothelial Carcinoma Bladder

NCT04924179 2022-08-17

Tislelizumab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With Advanced CRC

Patients With Advanced Metastatic Colorectal Cancer

NCT05290116 2022-08-05

HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma

17 enrolled

Cholangiocarcinoma

NCT05469061 2022-07-21

Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC

17 enrolled

Esophageal Squamous Cell Carcinoma

NCT05461235 2022-07-18

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

1 enrolled

PD-1 Antibody

NCT05247619 2022-07-15

A Clinical Study to Explore the Efficacy and Safety of Tislelizumab in Combination With Bevacizumab and Chemotherapy in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer

49 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05448885 2022-07-08

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

50 enrolled

Nasopharyngeal Carcinoma

NCT05310383 2022-04-11

Tislelizumab and Radiotherapy for Recurrent Cervical Cancer

58 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT04921995 2022-04-04

RETICULA-NPC

40 enrolled

Nasopharyngeal Carcinoma

NCT05291052 2022-03-22

Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract Tumors

20 enrolled

Biliary Tract Tumor

NCT05254899 2022-02-24

Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL

54 enrolled

Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT05241132 2022-02-15

Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary